When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CNCE - Concert Pharmaceuticals: A Balanced Risk/Reward
Concert Pharmaceuticals Inc.
Concert Pharmaceuticals has a JAK inhibitor for alopecia areata (AA) that may be superior to competitive products.
The company cites a figure of 1.5m US patients with AA. Published literature cites a prevalence of 700,000 patients and only 300,000 with moderate to severe AA.
The first JAK inhibitor is now approved for the treatment of severe AA.
A key question for investors is what peak sales figure for CTP-543 can investors reasonably expect, and how does that impact the risk/reward.